RBP1 and glioblastoma: In particular, Norcyclobenzaprine and Protriptyline show significant potential against GBM; they are predicted to bind targets such as PARP1, PARP2, PRG, RBP1 to disrupt DNA repair pathways, respond to hormone and DNA-templated transcription and the retinoic acid signaling pathway, further effect survival-related pathways including cell cycle arrest, response to ER stress, glucose transport, and regulation of autophagy.